These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19888522)

  • 1. The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoids.
    Rudd TR; Skidmore MA; Guimond SE; Holman J; Turnbull JE; Lauder RM; Fernig DG; Yates EA
    Thromb Haemost; 2009 Nov; 102(5):874-8. PubMed ID: 19888522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From unfractionated heparins to low molecular weight heparins.
    Hirsh J
    Acta Chir Scand Suppl; 1990; 556():42-50. PubMed ID: 1705072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight.
    Grims RH; Weger W; Reiter H; Arbab E; Kränke B; Aberer W
    Br J Dermatol; 2007 Sep; 157(3):514-7. PubMed ID: 17573880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosaminoglycans alter the conformation of interferon-gamma.
    Balasubramanian V; Ramanathan M
    Cytokine; 2000 May; 12(5):466-71. PubMed ID: 10857760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosaminoglycan origin and structure revealed by multivariate analysis of NMR and CD spectra.
    Rudd TR; Skidmore MA; Guimond SE; Cosentino C; Torri G; Fernig DG; Lauder RM; Guerrini M; Yates EA
    Glycobiology; 2009 Jan; 19(1):52-67. PubMed ID: 18832453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
    Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
    Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update.
    Jappe U
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):605-13. PubMed ID: 17102645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
    Jappe U; Juschka U; Kuner N; Hausen BM; Krohn K
    Contact Dermatitis; 2004 Aug; 51(2):67-72. PubMed ID: 15373846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of heparins and heterogeneity of low molecular weight heparins.
    Bianchini P; Liverani L; Spelta F; Mascellani G; Parma B
    Semin Thromb Hemost; 2007 Jul; 33(5):496-502. PubMed ID: 17629846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular weight molluscan glycosaminoglycan from bivalve Katelysia opima (Gmelin).
    Vijayabaskar P; Balasubramanian T; Somasundaram ST
    Methods Find Exp Clin Pharmacol; 2008 Apr; 30(3):175-80. PubMed ID: 18597000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production and chemical processing of low molecular weight heparins.
    Linhardt RJ; Gunay NS
    Semin Thromb Hemost; 1999; 25 Suppl 3():5-16. PubMed ID: 10549711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of Heparinoids Premixed with Tumor-Derived Extracellular Vesicles.
    Manandhar S; Park J; Kothandan VK; Lee J; Alam F; Jee JP; Hwang J; Byun Y; Hwang SR
    Bioconjug Chem; 2018 Nov; 29(11):3757-3767. PubMed ID: 30372043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultra-low-molecular-weight heparins: precise structural features impacting specific anticoagulant activities.
    Lima MA; Viskov C; Herman F; Gray AL; de Farias EH; Cavalheiro RP; Sassaki GL; Hoppensteadt D; Fareed J; Nader HB
    Thromb Haemost; 2013 Mar; 109(3):471-8. PubMed ID: 23329070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases.
    Ofosu FA
    Thromb Res; 2008; 123(1):5-7. PubMed ID: 18284938
    [No Abstract]   [Full Text] [Related]  

  • 18. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Commentary.
    Gómez-Outes A; Gómez de la Bárcena C; Martínez-González J
    Br J Dermatol; 2008 Apr; 158(4):869-70. PubMed ID: 18284394
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of anticoagulant heparinoids by immunoprofiling.
    Wijnhoven TJ; van de Westerlo EM; Smits NC; Lensen JF; Rops AL; van der Vlag J; Berden JH; van den Heuvel LP; van Kuppevelt TH
    Glycoconj J; 2008 Feb; 25(2):177-85. PubMed ID: 17909966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.